Trajan Group Holdings Ltd · ASX:TRJ
Trajan — H1 FY2025 Earnings Presentation
14 slides from Trajan's earnings presentation, Feb 27, 2025
Slide 1: H1 FY25 Financial Results
Science that benefits people Enriching personal health through scientific tools and solutions 27 FEBRUARY 2025 H1 FY25 Financial Results Stephen Tomisich Founder, CEO & Managing Director Alister Hodges CFO
Slide 2: Trajan Scientific and Medical
Trajan Scientific and Medical Business segments We are a global developer and manufacturer of analytical and life sciences products and devices that was founded to make Components & Consumables Capital Equipment a positive impact on human wellbeing. High precision products and Robotic workflow autom
Slide 3: Science Benefitting People
Science Benefitting People Microsampling devices blasted into space with SpaceX And so much more • Blood microsamples collected in zero gravity. • Automated HDX system leads the world in • Harpera microbiopsy device (IUO) has been doubling enabling improved understanding of year-on-year with revenue
Slide 4: H1 FY2025 Financial Summary
H1 FY2025 Financial Summary Group Revenue UP Group nEBITDA UP $81.0M 6.0% $7.9M 97.2% PCP: $76.4M PCP:$4.0M 82.1 81.0 H1 FY23 81.5 10.7 H1 FY23 80.1 78.6 10.1 76.4 H1 FY24 H1 FY24 8.9 63.9 8.3 7.9 6.0 43.7 June 2023 December 4.4 2024 4.0 Revenue nEBITDA - Group Cash Proforma Operating Balance Gross
Slide 5: Operational Environment – Highlights and Considerations
Operational Environment – Highlights and Considerations • Operating and financial performance improvements over H1 FY24 with record revenue achieved in H1FY25. Building into H2 with customer demand momentum and strong order book. • Operating and integration synergies evident. LEAP Technologies and A
Slide 6: Components & Consumables
Components & Consumables Net Revenue Proforma nEBITDA $48.9M Gross Profit $16.3M (PCP:$46.6M) Margin 41.2% (PCP:$14.7M) (PCP:39.6%) 60.0 50.0 49.3 49.6 48.9 50.0 46.6 40.0 38.2 35.0 30.0 18.2 17.6 • Revenue for several core product lines increasing by 15- 20.0 15.6 16.3 12.3 13.3 14.7 20% over PCP.
Slide 7: Capital Equipment
Capital Equipment Net Revenue Proforma nEBITDA $29.9M Gross Profit $5.6M (PCP:$27.6M) Margin 36.2% (PCP:$5.1M) (PCP:39.8%) 30.2 29.9 27.1 27.6 26.3 22.9 8.6 • Order book grew by $2.4M and was $11.4M at 6.7 5.3 5.1 4.6 5.6 December 2024. 3.9 1.5 • H1 saw a return of momentum in Pharmaceutical Capital
Slide 8: Disruptive Technologies
Disruptive Technologies Net Revenue: Proforma nEBITDA $2.2M Gross Profit ($1.0M) (PCP:$2.2M) Margin 53.0% (PCP:($2.9M)) (PCP:39.1%) 3.5 10.0 3.0 3.0 8.0 2.7 2.7 2.6 2.5 6.0 2.2 2.2 2.0 4.0 1.5 2.0 1.0 -1.0 - • Advanced the commercial activation program for Versiti -1.1 -1.5 -2.1 -2.0 (formerly Hummi
Slide 9: Cashflow Summary
Cashflow Summary Dec 2024 Dec 2023 • Movement in net working capital due to increase in inventories ($M) ($M) $2.7M, increase in receivables $0.3M, decrease in other Normalised EBITDA1 7.9 4.0 assets $1.2M, increase in payable $2.1M and increase in Income tax payments (0.2) (0.9) deferred revenue $1
Slide 10: Margin Protection & Enhancement
Margin Protection & Enhancement • Proforma Gross Margin was 39.7% (PCP 39.7%). • Components & Consumables reported a 1.6 percentage points improvement on PCP to 41.2%. • Capital Equipment segment was 36.2% (PCP 39.8%) and was lower due to the product mix being biased towards Food with consideration
Slide 11: Financial Guidance Re-confirmed
Financial Guidance Re-confirmed Net Revenue Group nEBITDA • Components & Consumables expected to $160.0M-$165.0M $17.0M-$19.0M continue at historical growth rates with the strengthening of Pharmaceutical sector orders. • Whilst customer feedback and Capital Equipment Trajan Revenue Track Record orde
Slide 12: Fundamentals Remain Strong
Fundamentals Remain Strong • Return to historic performance and growth profile. • Large defensive end-markets with structural growth drivers. • Robust business model, pursued with discipline. • Bluechip, sticky customer base. • High barriers to market entry with significant investment in global infr
Slide 13: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 27th February 2025. The information in the presentation is provided for information purposes only, is in summary form and does n
Slide 14: www.trajanscimed.com
= TRAJAN | Science that benefits people www.trajanscimed.com
Trajan Group Holdings — H1 FY2025 Earnings Presentation on 6ix